Amphastar Pharmaceuticals (AMPH) Operating Leases (2019 - 2026)

Amphastar Pharmaceuticals has reported Operating Leases for 8 years, with the latest figure at $67.5 million in Q2 2026.

• On a quarterly basis, Operating Leases rose 73.16% year-over-year to $67.5 million in Q2 2026; TTM through Jun 2026 was $67.5 million, a 73.16% increase from a year earlier, with the FY2025 full-year figure at $37.7 million, down 10.02% from the prior year.
• Operating Leases was $67.5 million for Q2 2026 at Amphastar Pharmaceuticals, down from $75.1 million in the prior quarter.
• The five-year high for Operating Leases was $75.1 million in Q1 2026, with the low at $23.7 million in Q4 2022.
• Average Operating Leases over 5 years is $35.3 million, with a median of $29.6 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Operating Leases declined 10.02% in 2025, then jumped 84.59% in 2026.
• Over 5 years, Operating Leases stood at $23.7 million in 2022, then climbed by 25.44% to $29.7 million in 2023, then surged by 40.91% to $41.9 million in 2024, then retreated by 10.02% to $37.7 million in 2025, then jumped by 79.04% to $67.5 million in 2026.
• The last three Operating Leases figures came in at $67.5 million (Q2 2026), $75.1 million (Q1 2026), and $37.7 million (Q4 2025), per Business Quant data.